A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders

2025-522368-34-00 Protocol MNA-001-01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 5 Sep 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol MNA-001-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 123
Countries 1
Sites 1

Alzheimer’s Disease

Key facts

Sponsor
Muna Therapeutics ApS
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
5 Sep 2025 → ongoing
Decision date (initial)
2025-09-04
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer’s Disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Muna Therapeutics ApS

Sponsor organisation
Muna Therapeutics ApS
Address
Nordre Fasanvej 215
City
Frederiksberg
Postcode
2000
Country
Denmark

Scientific contact point

Organisation
Muna Therapeutics ApS
Contact name
Moneypenny Answering Service on behalf of Muna Therapeutics ApS

Public contact point

Organisation
Muna Therapeutics ApS
Contact name
Moneypenny Answering Service on behalf of Muna Therapeutics ApS

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 123 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-09-05 2025-09-08

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-14 Netherlands Acceptable
2025-09-04
2025-09-04
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-21 Netherlands Acceptable
2025-09-04
2025-10-21
3 SUBSTANTIAL MODIFICATION SM-1 2026-02-04 Netherlands Acceptable
2026-02-26
2026-02-26